Drug intelligence / Profile preview

blueberry juice-University of Oslo

Development stage: Unknown
Lead developer: University of Oslo
Administration: Oral

Overview

Blueberry juice is a dietary intervention being studied by the University of Oslo for its potential cardioprotective effects. It is rich in polyphenols, particularly anthocyanins, which are believed to exert antioxidant and anti-inflammatory effects. In the specific clinical trial context, it is administered as a 1-liter daily supplement to individuals with elevated cardiovascular risk factors to evaluate its impact on blood pressure, lipid profiles, and markers of oxidative stress and inflammation. The intervention aims to leverage the high concentration of bioactive compounds in blueberries to modulate biological pathways associated with cardiovascular disease progression.

Other names: Blueberry juice

Targets

NF-κB

Beyond the preview

Go deeper on blueberry juice-University of Oslo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on blueberry juice-University of Oslo.

Explore the full profile